VANCOUVER, BC– Zymeworks Inc. has opened a new state-of-the-art, 10,000 square foot laboratory facility in Vancouver, BC.
According to company president and CEO, Dr. Ali Tehrani, the new lab will provide the company with increased control over its discovery research activities including antibody generation, medicinal chemistry, bioconjugation for generating antibody drug conjugates and developing multi-functional proteins.
“Zymeworks’ new lab is an investment in our future, it will enable us to perform our own internal research and development in a fully integrated manner,” Tehrani said. “As the Zymeworks family continues to grow, so do our requirements, and the capabilities our new lab provides demonstrate our commitment to efficiently advance and expand our therapeutic pipeline.”
He adds that having Zymeworks’ discovery components together in one centralized location will enhance the company’s ability to expedite certain processes on an as-needed basis.